Multidrug
resistance (MDR) and adverse effects of chemotherapeutic
agents are severe issues in clinical cancer treatment. Due to the
dysregulation of enzymes in the cancer cells, enzyme-responsive drug
delivery systems (DDSs) have been considered as a viable technology
for cancer chemotherapy. In the present work, doxorubicin (DOX) is
visible after leaving from AuNR–LAX. After treatment with AuNR–LAX,
the drug resistance index of DOX-resistant MCF-7/ADR cells was reduced
from extremely high 955.0 to 1.7, implying high potential of AuNR–LAX
in the MDR phenotype cancer treatment. In addition, the cellular viability
of both MCF-7 and MCF-7/ADR cells decreased from 50% to 80% after
treatment with AuNR–LAX along (equivalent DOX concentration
= 2.3 μg/mL, Au concentration = 30 μg/mL) to below 10%
after AuNR–LAX treatment plus radiation of 808 nm, due to the
NIR photothermal effect of AuNRs. Human bronchial epithelial cell
line 16HBE was chosen to evaluate the adverse effect of AuNR–LAX
on the normal cells. At the low concentration, the cytotoxicity of
LAX and AuNR–LAX is comparable for breast cancer cell MCF-7
and normal cell 16HBE. It is noted that, at high concentration (with
equivalent DOX concentration = 13.1 μg/mL, Au concentration
= 167.7 μg/mL), the cellular viability of 16HBE cells is over
50%, whereas that of MCF-7 cancer cells is close to 0, implying the
potential of AuNR–LAX in reducing the adverse effects of DOX
against normal cells/tissues. Overall, AuNR–LAX showed high
potential in overcoming MDR and alleviating adverse effect on normal
cells.